Market Newsdesk

SANTA CLARA, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) — Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced it will hold its fourth quarter and fiscal year 2026 earnings conference call on Thursday, February 26, 2026 at 1:30 p.m. (Pacific Time). The company will issue its earnings release after the market closes that same day.

Those interested in asking a question on the call are required to register online in advance. Upon completing the first step of the online registration process, please note a registration verification code will be emailed to you, and this code must be entered to complete the online registration process. Once registered and verified, the dial-in numbers will be sent to the registered email with a personal identification number (PIN). When dialing in for the live call, the PIN number must be provided to access the call.

The live webcast of the conference call, and a webcast replay, will be available at: http://investor.ambarella.com/events.cfm

About Ambarella

Ambarella’s products are used in a wide variety of edge AI and human vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, telematics, driver/cabin monitoring, autonomous driving, edge infrastructure, drones and other robotics applications. Ambarella’s low-power systems-on-chip (SoCs) offer high-resolution video compression, advanced image and radar processing, and powerful deep neural network processing to enable intelligent perception, sensor fusion, and planning. For more information, please visit www.ambarella.com.

Contact:
Louis Gerhardy
VP Corporate Development
408-636-2310
[email protected]

BEIJING, Feb. 05, 2026 (GLOBE NEWSWIRE) — Yimutian Group (“Yimutian” or the “Company”), a leading digital agriculture platform in China, announced that it has entered into a preliminary acquisition agreement with Hunan Jiufeng Agriculture Co., Ltd. (“Jiufeng Agriculture”), a well-established producer of premium camellia oil products.

The proposed transaction represents a strategic shift for Yimutian as it builds an integrated agricultural ecosystem spanning production, circulation, and consumer markets. By integrating Jiufeng Agriculture’s origin-based resources with its existing digital infrastructure, the Company seeks to enhance product standardization, traceability, and commercialization efficiency. This move allows Yimutian to extend its capabilities beyond B2B services and further into consumer-facing segments.

Founded in 2012, Jiufeng Agriculture operates a vertically integrated camellia oil business covering oil-tea cultivation, raw material processing, oil pressing, refining, and branded product sales. The company has invested approximately RMB 110 million in high-standard oil-tea plantations totaling nearly 30,000 mu (approximately 2,000 hectares) and participated in an agricultural consortium managing more than 150,000 mu of oil-tea farmland.

Jiufeng Agriculture is located in Yueyang County, Hunan Province, one of China’s nationally designated key camellia oil production regions, known for its favorable climate conditions and long-standing cultivation heritage. The region provides stable access to high-quality raw materials, supporting product consistency and long-term supply reliability.

Yimutian plans to deploy its digital and AI-enabled technologies across multiple stages of the camellia oil value chain. Data-driven tools will support planting optimization at the production level, while intelligent manufacturing systems will enhance efficiency and quality control during processing. On the consumer side, the Company intends to leverage digital distribution channels and AI-powered marketing to broaden market reach domestically and internationally.

“Our long-term vision is to create a technology-driven agricultural ecosystem that connects production with consumption,” said Jinhong Deng, Chairman and Chief Executive Officer of Yimutian Group. “By applying AI and data throughout the value chain, we aim to improve production efficiency, strengthen quality assurance, and unlock greater commercial value for agricultural products. Ultimately, our goal is to make every acre of farmland more valuable.”

The proposed transaction is subject to further due diligence, negotiation of definitive agreements, and customary closing conditions. There can be no assurance that the transaction will be completed on the terms currently contemplated, or at all.

About Yimutian Inc:

Yimutian Inc, is a leading agricultural B2B platform in mainland China. Over a decade, the company has been dedicated to digitalizing China’s agricultural product supply chain infrastructure to streamline the agricultural product transaction process, and making it efficient, transparent, secure, and convenient.

For more information, please visit https://ir.ymt.com/ 

About
Jiufeng Agriculture:

Hunan Jiufeng Agricultural Development Co., Ltd., founded in 2012, is an edible oil processing and sales enterprise integrating camellia oil planting, camellia fruit processing, as well as the pressing and refining of camellia seed oil and rapeseed oil. With an investment of 110 million yuan, the company has planted nearly 30,000 mu of high-standard camellia oleifera forests, and has joined hands with nearly 150,000 mu of camellia oleifera forests under 13 specialized camellia oil cooperatives to form a Hunan agricultural industrial consortium.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, these forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

For investor inquiries, please contact:

Email: [email protected] 
Phone: +86 1057086561

For media inquiries, please contact:

Email: [email protected]

ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the pricing of its initial public offering of 12,500,000 American Depositary Shares (“ADSs”) representing 12,500,000 of its common shares, at a public offering price of $16.00 per ADS. The gross proceeds to Agomab from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $200.0 million. All of the ADSs are being offered by Agomab. In addition, Agomab has granted the underwriters a 30-day option to buy an additional 1,875,000 ADSs at the initial public offering price, less underwriting discounts and commissions.

The ADSs are expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “AGMB”. The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen are acting as joint book-running managers for the offering.

A registration statement relating to this offering has been filed with the Securities and Exchange Commission and was declared effective on January 30, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from:
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; and Van Lanschot Kempen (USA) Inc., 880 Third Avenue, 17th floor, New York, New York 10022, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. The transaction to which this press release relates will only be available to, and will be engaged in only with, in member states of the European Economic Area (including Belgium), persons falling within the meaning of Article 2(e) of Regulation (EU) 2017/1129 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and in the United Kingdom, investment professionals falling within article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), persons falling within article 49 (2), (a) to (d) of the Order and other persons to whom it may lawfully be communicated.

About Agomab

Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Agomab’s product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches. Agomab’s mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding Agomab’s expectations regarding the commencement of trading of its ADSs on the Nasdaq Global Select Market, the completion and timing of the closing of the offering and the anticipated gross proceeds from the offering. Forward-looking statements are based on Agomab’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in biopharmaceutical product development. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” section of the registration statement filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Agomab undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information on this page as current or accurate after its publication date.

Contacts

Investors

Sofie Van Gijsel
VP of Investor Relations
E-Mail: [email protected]
Phone: +1 781 296 1143

Media

Stephanie May or Joe Rayne
Trophic Communications
E-Mail: [email protected]
Phone: +49 171 1855682

BEIJING, China, Feb. 05, 2026 (GLOBE NEWSWIRE) — Yimutian Group (“Yimutian” or the “Company”), a leading digital agriculture platform in China, announced that it has entered into a strategic cooperation agreement (the “agreement” ) with regional partners to jointly develop a large-scale integrated agricultural project in Huazhou City, Guangdong Province.

The project, known as the Jianjiang Farmland Integrated Development Initiative, covers a planned area of more than 21,000 mu (approximately 1,400 hectares) and represents Yimutian’s continued expansion of its technology-enabled, origin-based agricultural development model.

The initiative focuses on improving land utilization efficiency, advancing digital farm management, and building a scalable agricultural production and circulation ecosystem. It is designed to support standardized farming, supply-chain optimization, and value-added agricultural commercialization.

Under the agreement, Yimutian will contribute its digital platform capabilities, data systems, and AI-enabled agricultural technologies, while local partners will support land coordination, infrastructure integration, and project execution. The collaboration aims to create a replicable model for large-scale modern agriculture development. The project will be developed across three core pillars:

• First, land consolidation and infrastructure optimization will be carried out to improve soil quality, irrigation systems, and field connectivity, enabling the creation of contiguous high-standard farmland and enhancing overall productivity.
• Second, Yimutian plans to deploy digital technologies, including AI-driven planting optimization, market forecasting tools, and supply-chain management systems, to support end-to-end digital oversight from cultivation through distribution.
• Third, the project is expected to promote value-chain extension through branding, processing, and integrated agricultural services, supporting higher-value commercialization of regional agricultural products.

The Company also plans to implement inclusive participation mechanisms for local farmers, including land leasing, on-site employment opportunities, and cooperative participation models, with the goal of aligning long-term productivity improvements with sustainable income generation.

“This project reflects our strategy of extending digital agriculture from online platforms into origin-based, large-scale production systems,” said Jinhong Deng, Chairman and Chief Executive Officer of Yimutian Group. “By combining digital infrastructure, AI technology, and market connectivity, we aim to build efficient, standardized, and scalable agricultural models that can be replicated across regions.”

The Huazhou initiative marks Yimutian’s second integrated land development project in Maoming City. The Company previously launched a similar project in Maonan District, which is currently in operation. Together, the two projects represent a combined development area of approximately 35,000 mu, strengthening Yimutian’s presence in one of southern China’s key agricultural regions.

Yimutian has accumulated extensive experience in applying digital technologies to agricultural production and circulation. In prior initiatives, the Company supported regional specialty crops through digital market systems and developed technology-enabled demonstration farms using IoT monitoring and data-driven cultivation models. These projects have demonstrated improvements in yield efficiency, resource utilization, and supply-chain coordination.

The large-scale, technology-enabled agricultural development initiatives are expected to serve as important building blocks for the modernization of China’s agricultural industry, while creating long-term value through improved productivity, food quality, and market efficiency.

About Yimutian Inc:

Yimutian Inc, is a leading agricultural B2B platform in mainland China. Over a decade, the company has been dedicated to digitalizing China’s agricultural product supply chain infrastructure to streamline the agricultural product transaction process, and making it efficient, transparent, secure, and convenient.

For more information, please visit https://ir.ymt.com/ 

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, these forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

For investor inquiries, please contact:

Email: [email protected] 
Phone: +86 1057086561

For media inquiries, please contact:

Email: [email protected]